Home Cart Sign in  
Chemical Structure| 2728667-27-2 Chemical Structure| 2728667-27-2

Structure of Zongertinib
CAS No.: 2728667-27-2

Chemical Structure| 2728667-27-2

Zongertinib

CAS No.: 2728667-27-2

Zongertinib is an effective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. This compound exhibits significant anti-tumor activity, especially suitable for research on various solid tumors with potential applications in cancer therapy.

Synonyms: BI 1810631

4.5 *For Research Use Only !

Cat. No.: A1942329 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇǶÊÊ Inquiry Inquiry
5mg łËó¶ÊÊ Inquiry Inquiry
10mg łÍͶÊÊ Inquiry Inquiry
50mg łÇÍď¶ÊÊ Inquiry Inquiry
100mg łËÍó¶ÊÊ Inquiry Inquiry
250mg łÍËǶÊÊ Inquiry Inquiry
1g łÇÇÇǶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łÇǶÊÊ

  • 5mg

    łËó¶ÊÊ

  • 10mg

    łÍͶÊÊ

  • 50mg

    łÇÍď¶ÊÊ

  • 100mg

    łËÍó¶ÊÊ

  • 250mg

    łÍËǶÊÊ

  • 1g

    łÇÇÇǶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zongertinib

CAS No. :2728667-27-2
Formula : C29H29N9O2
M.W : 535.60
SMILES Code : C=CC(NC1CCN(C2=NC=C(N=CN=C3NC4=CC=C(OC5=CC=C6N(C)C=NC6=C5)C(C)=C4)C3=N2)CC1)=O
Synonyms :
BI 1810631
MDL No. :N/A

Safety of Zongertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Zongertinib

RTK

Isoform Comparison

Biological Activity

Description
Zongertinib (BI 1810631) is a potent and selective inhibitor of HER2 and EGFR tyrosine kinases, with IC50 values of 13 nM and 579 nM, respectively. It exhibits antitumor activity and holds promise for research in various solid tumors [1][2][3].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06581432 Solid Tumours PHASE2 RECRUITING 2027-09-30 Alaska Oncology and Hematology... More >>, LLC, Anchorage, Alaska, 99508, United States|University of Arizona Comprehensive Cancer Center, Phoenix, Arizona, 85021, United States|Precision Next Gen Oncology, Beverly Hills, California, 90212, United States|Scripps Health, La Jolla, California, 92037, United States|Valkyrie Clinical Trials, Los Angeles, California, 90067, United States|University of California Los Angeles, Los Angeles, California, 90095, United States|Yale University, New Haven, Connecticut, 06520, United States|BRCR Global, Tamarac, Florida, 33321, United States|Illinois Cancer Specialists, Niles, Illinois, 60005, United States|Maryland Oncology Hematology, P.A, Rockville, Maryland, 20850, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Mount Sinai School of Medicine, New York, New York, 10029, United States|Memorial Sloan Kettering Cancer Center Basking Ridge, New York, New York, 10065, United States|Alliance Cancer Specialists, PC, Horsham, Pennsylvania, 19044, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|VCU Health Community Memorial Hospital, South Hill, Virginia, 23970, United States|Macquarie University, Macquarie University, New South Wales, 2113, Australia|Northern Cancer Institute, St Leonards, New South Wales, 2065, Australia|Princess Alexandra Hospital, Wooloongabba, Queensland, 4102, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, 6008, Australia|Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium|Universitair Ziekenhuis Antwerpen - UZA, Edegem, 2650, Belgium|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Agency - Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 1Z9, Canada|Hopital Notre-Dame du CHUM, Montreal, Quebec, H2X 0C1, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, H4A 3J1, Canada|The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China|Shanghai East Hospital, Shanghai, 200126, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Institut Bergonié, Bordeaux, 33000, France|Centre Georges-Fran?ois Leclerc, Dijon, 21079, France|H?pital de la Milétrie - CHU de Poitiers, Poitiers, 86000, France|Institut Gustave Roussy, Villejuif, 94800, France|Universit?tsklinikum Gie?en, Gie?en, 35392, Germany|Asklepios Klinik Altona, Hamburg, 22763, Germany|Universit?tsklinikum Leipzig, Leipzig, 04103, Germany|Universit?tsklinikum Mannheim, Mannheim, 68167, Germany|Klinikum rechts der Isar der Technischen Universit?t München, München, 81675, Germany|Az. Ospedaliera Umberto I di Ancona, Ancona, 60020, Italy|Istituto Scientifico Romagnolo, Meldola (FC), 47014, Italy|Ospedale Niguarda Ca' Granda, Milano, 20162, Italy|AOU Università degli Studi della Campania Luigi Vanvitelli, Napoli, 80131, Italy|Aichi Cancer Center Hospital, Aichi, Nagoya, 464-8681, Japan|National Cancer Center Hospital East, Chiba, Kashiwa, 277-8577, Japan|Osaka International Cancer Institute, Osaka, Osaka, 541-8567, Japan|Shizuoka Cancer Center, Shizuoka, Sunto-gun, 411-8777, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, 104-0045, Japan|Japanese Foundation for Cancer Research, Tokyo, Koto-ku, 135-8550, Japan|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Nederlands Kanker Instituut, Amsterdam, 1066 CX, Netherlands|Radboudumc, Nijmegen, 6525 GA, Netherlands|Oslo Universitetssykehus HF, Radiumhospitalet, Oslo, N-0379, Norway|Pan American Center for Oncology Trials, LLC, Rio Piedras, 00935, Puerto Rico|Hospital Universitario A Coru?a, A Coru?a, 15006, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Clínica Universidad de Navarra, Pamplona, 31008, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain Less <<
NCT06075277 Healthy PHASE1 COMPLETED 2024-01-02 CRS Clinical Research Services... More >> Berlin GmbH, Berlin, 13627, Germany Less <<
NCT06360081 Healthy PHASE1 COMPLETED 2024-06-30 CRS Clinical Research Services... More >> Mannheim GmbH, Mannheim, 68167, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.34mL

1.87mL

0.93mL

18.67mL

3.73mL

1.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories